Drug Database
CI

ciprofol (HSK 3486 / ciprofol / Cyclopofol)

✓ Approved

Haisco Pharmaceutical Group · 小分子 · 小分子

什么是 ciprofol?

ciprofol 是一种小分子,由Haisco Pharmaceutical Group研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

商品名HSK 3486, ciprofol, Cyclopofol
公司Haisco Pharmaceutical Group
药物类别小分子
给药途径Injectable (Others), Intravenous (IV)
状态Approved

治疗适应症

ciprofol 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Nervous system disordersAnaesthesia✓ Approved
Nervous system disordersSensory loss✓ Approved

相关研究文献

PubMedDrug design, development and therapy2026-11-17

Optimal Dose of Ciprofol for Anesthesia Induction in Older Hypertensive Patients with Elevated Baseline Systolic Blood Pressure: A Bayesian Phase 1/2 Trial.

Fang Jiajia J, Gao Yang Y, Wang Yi Y, Wang Jiang J et al.

To identify the optimal ciprofol induction dose for older hypertensive patients with elevated baseline invasive systolic blood pressure (SBP ≥ 140 mmHg) using a Bayesian adaptive design. This single-center, seamless phase 1/2 trial enrolled 51 hypertensive patients aged 65-80 years with baseline invasive SBP ≥ 140 mmHg undergoing elective non-cardiac procedures. General anesthesia was induced with ciprofol (0.20-0.40 mg/kg), sufentanil (0.4 µg/kg), and rocuronium (1.0 mg/kg). Phase 1 used the Bayesian Optimal Interval (BOIN) design to determine the maximum tolerated dose (MTD). Dose-limiting toxicity (DLT) was defined as post-induction hypotension (PIH; mean arterial pressure [MAP] < 65 mmHg from induction to 3 minutes post-intubation). The target DLT probability was set at 45% to accommodate the high baseline hypotension risk in this cohort. Phase 2 adopted the Bayesian Optimal Phase 2 (BOP2) design to find the optimal biological dose (OBD), evaluating both efficacy (loss of consciousness within 2 minutes without rescue dosing) and safety. Phase 1 (n = 30) identified the MTD at 0.35 mg/kg (posterior mean PIH incidence: 33%, 95% credible interval [CrI]: 11%-61%). Phase 2 (n = 21) selected 0.25 mg/kg (n = 12) as the OBD, achieving a high induction success rate (91%, 95% CrI: 71%-99%) alongside a lower PIH risk (25%, 95% CrI: 6%-52%). The peak MAP after endotracheal intubation was higher with 0.25 mg/kg than 0.35 mg/kg (126.1 ± 20.9 vs 97.8 ± 14.8 mmHg; Bonferroni-adjusted P = 0.002). Guided by the Bayesian algorithm, 0.25 mg/kg was identified as the protocol-selected OBD for older hypertensive patients with baseline invasive SBP ≥ 140 mmHg, balancing reliable anesthesia with acceptable hypotension risks. However, compared with 0.35 mg/kg, this lower dose less effectively blunts intubation-induced hypertensive surges and requires careful hemodynamic monitoring.

PMID 43042220
阅读全文 →
PubMedDrug design, development and therapy2026-11-14

Ciprofol-Based Total Intravenous Anesthesia During Pediatric Laparoscopic Surgery: A Double-Blind, Randomized Controlled, Non-Inferiority Clinical Trial.

Xu Li L, Pan Ruochen R, Dai Xinyu X, Xu Aijun A

This double-blind, randomized controlled trial evaluated whether ciprofol is non-inferior to propofol as the primary agent for total intravenous anesthesia (TIVA) in pediatric laparoscopic surgery, with respect to extubation time and safety profile. Children aged 2-12 years (ASA I-II) undergoing laparoscopic surgery were randomly assigned (1:1) to receive either ciprofol or propofol for TIVA. The primary outcome was time to extubation, with a predefined non-inferiority margin (Δ) of 4.8 minutes. Secondary outcomes included recovery metrics, emergence delirium, pain scores, hemodynamic profiles, and safety indicators. A total of 86 children (43 per group) were enrolled. Extubation time was 17.3±4.9 min in the ciprofol group and 20.1±4.9 min in the propofol group (mean difference, -2.79 min; 95% CI, -4.9 to -0.7). The upper bound of the 95% CI (-0.73 min) was well below the non-inferiority margin of 4.8 min, confirming non-inferiority (one-sided P < 0.0001). Anesthesia and surgery times, recovery metrics, and pain scores did not differ significantly between groups. The incidence of emergence delirium was similar (7.0% vs 2.3%, P=0.616). In exploratory analyses, individuals in the ciprofol group seemed to have overall higher systolic, diastolic, and mean blood pressure than those in the propofol group, while heart rate did not differ between the two groups. Ciprofol was non-inferior to propofol for extubation time in pediatric TIVA for laparoscopic surgery. Although exploratory analyses suggested potential favorable hemodynamic trends, larger multicenter studies are needed to evaluate comparative safety and clinical relevance.

PMID 43031678
阅读全文 →
PubMedMicrovascular research2026-11-08

Ciprofol protects against hypoxia/reoxygenation-induced injury in cardiac microvascular endothelial cells via the DYRK1A/PI3K/AKT signaling pathway.

Duan Lei L, He Xin X, He Guozun G, Zhou Tao T et al.

Myocardial ischemia/reperfusion (I/R) injury is a major complication following revascularization therapy for ischemic heart disease. Ciprofol (CIP) has been proven to protect cardiomyocytes from I/R-induced apoptosis, yet its role and underlying molecular mechanisms in vascular endothelial cells under hypoxia/reoxygenation (H/R) conditions remain incompletely elucidated. This study aimed to investigate the protective effects of CIP on I/R injury and its associated molecular mechanisms. C57BL/6 J mice were subjected to myocardial I/R injury. An in vitro H/R model was established in HUVECs to mimic myocardial I/R injury. The histopathological analysis was conducted by H&E staining. After H/R stimulation and/or CIP treatment, multiple cellular biological functions and molecular markers were assessed: cell viability and proliferation were detected via CCK-8 assay and EdU staining; colony formation ability was evaluated by cell cloning assay; cell migration capacity was measured through wound-healing assay; apoptosis was analyzed using TUNEL staining and Annexin V-FITC/PI flow cytometry; DNA damage was assessed by detecting the expression of ATM, ATR, γ-H2AX, and PARP1; cell cycle progression was determined by the expression of Cyclin B and cdc2; and the intrinsic mitochondrial apoptotic pathway was examined via the expression of Bcl-2, Bax, and Caspase-3. RNA-seq and untargeted metabolomics were conducted to identify the potential therapeutic mechanisms of CIP. DYRK1A, a key candidate gene, was validated by RNA-seq, metabolomics, and qRT-PCR. Overexpression and knockdown experiments were performed to confirm the role of the DYRK1A/PI3K/AKT signaling axis in CIP-mediated protection against H/R injury. The levels of cardiomyocyte apoptosis and myocardial enzymes were decreased in CIP-treated mice compared with the H/R group. In H/R-injured HUVECs, CIP dose-dependently restored cell viability, enhanced EdU incorporation, and accelerated cell invasion ability. Simultaneously, CIP reduced apoptosis and suppressed activation of caspase-3. Meanwhile, CIP alleviated DNA damage responses, shown decreased levels of γ-H2AX, ATM, and ATR, and restored PARP1 expression. Mechanistically, CIP significantly modulated tyrosine metabolism and downregulated DYRK1A expression, leading to the activation of the PI3K/AKT pathway. Notably, overexpression of DYRK1A abolished the protective effects of CIP, whereas DYRK1A knockdown reversed H/R-induced cell injury and further potentiated the protective function of CIP, confirming that the PI3K/AKT signaling pathway is a critical mediator of this process. CIP promotes proliferation, migration and invasion, while inhibiting apoptosis, in H/R-injured HUVECs by regulating the DYRK1A/PI3K/AKT signaling axis. These findings highlight CIP as a promising endothelial-protective agent for the treatment of I/R-related vascular disorders.

PMID 43000084
阅读全文 →
PubMedDrug design, development and therapy2026-11-06

Pump-Predicted Ciprofol Ce50 for Suppressing the Cardiovascular Response to Tracheal Intubation During Fixed Sufentanil-Esketamine Induction: An Age-Stratified Dixon Up-and-Down Study.

Lin Xiaofen X, Wan Qing Q, Huang Ruwen R, Li Rui R et al.

To estimate the ciprofol pump-predicted effect-site target concentration associated with a 50% probability of suppressing the cardiovascular response to tracheal intubation (Ce50) during fixed sufentanil-esketamine induction in two age cohorts. In this single-center, prospective, age-stratified Dixon up-and-down study, 53 adults undergoing elective surgery received sufentanil 0.3 μg/kg, esketamine 0.3 mg/kg, and ciprofol effect-site target-controlled infusion (TCI). Independent cohorts aged 45-64 and 65-79 years started at a pump-predicted target concentration (Ce) of 1.10 μg/mL, adjusted in 0.05 μg/mL steps. Ce50 was estimated by reversal-pair midpoints and Probit analysis. The trial was registered on March 31, 2026 (ChiCTR2600121464). Thirty-two middle-aged and 21 older adults were analyzed. Midpoint Ce50 was 0.975 μg/mL (approximate 95% confidence interval [CI], 0.910-1.040) and 1.096 μg/mL (1.072-1.121), respectively. Probit Ce50 was 0.991 μg/mL (95% CI, 0.773-1.103) and 1.112 μg/mL (1.078-1.152). At target Ce, mean arterial pressure fell by 19.2% ± 11.0% and 22.5% ± 12.5% from baseline. Hypotension occurred in 20/32 (62.5%) and 13/21 (61.9%) participants. These exploratory Ce50 estimates are specific to the CONCERT-III pump model and the studied co-induction and rescue protocol in small, nonrandomized cohorts at a single center. Frequent hypotension and norepinephrine use accompanied induction. The estimates do not establish an independent age effect or individual dosing targets and require external validation. Chinese Clinical Trial Registry, ChiCTR2600121464; prospectively registered March 31, 2026.

PMID 42992127
阅读全文 →
PubMedMolecular and cellular biochemistry2026-11-05

Ciprofol more broadly suppresses selected inflammatory markers than propofol in LPS-induced sepsis-associated encephalopathy.

Wan Qiuyan Q, Xu Suihan S, He Hongxia H, Wang Jun J et al.

To investigate and compare the anti-inflammatory and neuroprotective effects of ciprofol and propofol in lipopolysaccharide (LPS)-induced sepsis-associated encephalopathy(SAE). C57BL/6 N mice with LPS-induced SAE were treated with propofol(LP) or ciprofol(LC). Cognitive function was assessed by the Morris water maze (MWM) and novel object recognition (NOR) tests. Neuroinflammation and glial activation in the hippocampus were evaluated by histology, immunohistochemistry (IHC), immunofluorescence (IF), and RT-qPCR. Systemic and cellular inflammatory responses were measured by ELISA. In vitro, BV2 microglial cells were treated with LPS, LP, or LC, and their effects on neuronal viability were assessed in a co-culture system. Underlying mechanisms were explored by Western Blot and RT-qPCR. In vivo, both ciprofol and propofol produced comparable improvements in cognitive outcomes, and representative H&E- and Nissl-stained sections showed similar histological patterns. At the tested doses, ciprofol more broadly suppressed selected inflammatory markers. Systemically, ciprofol significantly reduced all three tested cytokines (TNF-α, IL-1β, and IL-6), whereas propofol significantly reduced TNF-α only. In the hippocampus, ciprofol produced greater reductions in Il-1β transcription and Iba-1-positive cells in the dentate gyrus. In vitro, ciprofol also produced greater reductions in selected proinflammatory mediators in BV2 cells. Mechanistically, ciprofol was associated with greater suppression of Nlrp3 mRNA, whereas the corresponding between-drug protein-level difference was not significant. In murine LPS-induced SAE, ciprofol and propofol produced comparable improvements in cognitive outcomes and similar histological observations, whereas ciprofol more broadly suppressed selected systemic and hippocampal inflammatory markers and was associated with greater Nlrp3 transcriptional suppression in BV2 cells at the tested doses or concentrations. These preclinical findings require confirmation in clinically relevant sepsis models and human studies before they can inform anesthetic selection in patients with sepsis.

PMID 42986375
阅读全文 →
PubMedBiology direct2026-11-05

Ciprofol induces ferroptosis and enhances anti-PD-1 efficacy via USP1-mediated GPX4 ubiquitination in hepatocellular carcinoma.

Wang Mengcong M, Shen Laien L, Huang Pingping P, Yuan Peigen P

Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis have shown promise in hepatocellular carcinoma (HCC), but resistance due to the immunosuppressive tumor microenvironment remains a major challenge. Ferroptosis, an iron-dependent form of regulated cell death, has emerged as a potential strategy to enhance anti-tumor immunity. Ciprofol, a novel propofol derivative widely used in clinical anesthesia, has not been explored for its role in cancer therapy. In this study, we evaluated the anti‑proliferative and pro‑ferroptotic effects of ciprofol in human HCC cell lines (Huh‑7, MHCC97‑H) and a mouse HCC line (H22) using CCK‑8, EdU, colony formation, Transwell, and flow cytometry assays. Ferroptosis was assessed by measuring ROS, Fe²⁺, MDA, SOD, and mitochondrial morphology via TEM. Molecular mechanisms were investigated by Western blot, qRT‑PCR, Co‑IP, ubiquitination assay, and surface plasmon resonance (SPR). In vivo efficacy was examined in xenograft (nude mice) and syngeneic (C57BL/6) models, and combination therapy with anti‑PD‑1 antibody was evaluated. Ciprofol inhibited HCC cell proliferation, migration, invasion, and epithelial‑mesenchymal transition (EMT) (IC₅₀: 43.7 µM for Huh‑7; 36.4 µM for MHCC97‑H). Mechanistically, ciprofol induced ferroptosis, evidenced by increased ROS, Fe²⁺, MDA, and typical mitochondrial shrinkage/cristae disruption, which were reversed by the ferroptosis inhibitor Fer‑1. Ciprofol did not alter GPX4 mRNA levels but promoted its ubiquitination and proteasomal degradation. Transcriptome analysis identified USP1 as a key downstream target. Ciprofol reduced USP1 expression, disrupted the USP1‑GPX4 interaction, and directly bound to USP1 (Kd = 1.5 µM). USP1 knockdown phenocopied ciprofol effects, inducing ferroptosis and suppressing HCC progression. In vivo, ciprofol (40 mg/kg) significantly reduced tumor growth, downregulated USP1/GPX4, and was well‑tolerated. Importantly, ciprofol improved tumor control when combined with anti-PD-1 antibody. In conclusion, ciprofol is a novel ferroptosis inducer that promotes GPX4 ubiquitination and degradation by suppressing USP1, exhibits potent anti‑HCC activity, and enhances the therapeutic efficacy of anti‑PD‑1 immunotherapy, representing a promising sensitizer for combined cancer treatment.

PMID 42983892
阅读全文 →

注册免费账户还可查看另外 319 篇文献

免费注册查看全部文献 →

了解更多ciprofol